Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

The H19-PEG10/IGF2BP3 axis promotes gastric cancer progression in patients with high lymph node ratios.

Ishii S, Yamashita K, Harada H, Ushiku H, Tanaka T, Nishizawa N, Yokoi K, Washio M, Ema A, Mieno H, Moriya H, Hosoda K, Waraya M, Katoh H, Watanabe M.

Oncotarget. 2017 Aug 5;8(43):74567-74581. doi: 10.18632/oncotarget.20209. eCollection 2017 Sep 26.

2.

IMP3 is upregulated in primary ovarian mucinous carcinoma and promotes tumor progression.

Zhu Q, Qu Y, Zhang Q, Lu L, Weng W, Zhang H, Zhang L, Ning Y, Wang Y.

Am J Transl Res. 2017 Jul 15;9(7):3387-3398. eCollection 2017.

3.

IMP3 and p16 expression in squamous cell carcinoma of the head and neck: A comparative immunohistochemical analysis.

Riener MO, Hoegel J, Iro H, Hartmann A, Agaimy A.

Oncol Lett. 2017 Aug;14(2):1665-1670. doi: 10.3892/ol.2017.6352. Epub 2017 Jun 8.

4.

Cytologic studies of the fallopian tube in patients undergoing salpingo-oophorectomy.

Chen H, Klein R, Arnold S, Chambers S, Zheng W.

Cancer Cell Int. 2016 Oct 1;16:78. eCollection 2016.

5.

Microsatellite alteration and immunohistochemical expression profile of chromosome 9p21 in patients with sporadic renal cell carcinoma following surgical resection.

El-Mokadem I, Lim A, Kidd T, Garret K, Pratt N, Batty D, Fleming S, Nabi G.

BMC Cancer. 2016 Jul 27;16:546. doi: 10.1186/s12885-016-2514-8.

6.

Expression of the cancer testis antigen IGF2BP3 in colorectal cancers; IGF2BP3 holds promise as a specific immunotherapy target.

Shantha Kumara H, Kirchoff D, Caballero OL, Su T, Ahmed A, Herath SA, Njoh L, Cekic V, Simpson AJ, Cordon-Cardo C, Whelan RL.

Oncoscience. 2015 Jul 1;2(6):607-14. eCollection 2015.

7.

Imp3 expression in benign and malignant thyroid tumors and hyperplastic nodules.

Kulaçoğlu S, Erkılınç G.

Balkan Med J. 2015 Jan;32(1):30-7. doi: 10.5152/balkanmedj.2015.15547. Epub 2015 Jan 1.

8.

IMP3 as a cytoplasmic biomarker for early serous tubal carcinogenesis.

Wang Y, Li L, Wang Y, Yuan Z, Zhang W, Hatch KD, Zheng W.

J Exp Clin Cancer Res. 2014 Jul 20;33:60. doi: 10.1186/s13046-014-0060-2.

9.

IMP3 signatures of fallopian tube: a risk for pelvic serous cancers.

Wang Y, Wang Y, Li D, Li L, Zhang W, Yao G, Jiang Z, Zheng W.

J Hematol Oncol. 2014 Jul 12;7:49. doi: 10.1186/s13045-014-0049-5.

10.

Immunohistochemical expression of IMP3 and p53 in inflammatory lesions and neoplastic lesions of the gastric mucosa.

Strehl JD, Hoegel J, Hornicek I, Hartmann A, Riener MO.

Int J Clin Exp Pathol. 2014 Apr 15;7(5):2091-101. eCollection 2014.

11.

Insulin-like growth factor-II mRNA-binding protein 3 predicts a poor prognosis for colorectal adenocarcinoma.

Lin L, Zhang J, Wang Y, Ju W, Ma Y, Li L, Chen L.

Oncol Lett. 2013 Sep;6(3):740-744. Epub 2013 Jul 12.

12.

Combined detection of p16(INK4a) and IMP3 increase the concordance rate between cervical cytologic and histologic diagnosis.

Wei Q, Fu B, Liu J, Xu J, Zhao T.

Int J Clin Exp Pathol. 2013 Jul 15;6(8):1549-57. Print 2013.

13.

Expression of the oncofetal protein IGF2BP3 in endometrial clear cell carcinoma: assessment of frequency and significance.

Fadare O, Liang SX, Crispens MA, Jones HW 3rd, Khabele D, Gwin K, Zheng W, Mohammed K, Parkash V, Hecht JL, Desouki MM.

Hum Pathol. 2013 Aug;44(8):1508-15. doi: 10.1016/j.humpath.2012.12.003. Epub 2013 Mar 1.

14.

A systematic analysis of miRNA transcriptome in Marek's disease virus-induced lymphoma reveals novel and differentially expressed miRNAs.

Lian L, Qu L, Chen Y, Lamont SJ, Yang N.

PLoS One. 2012;7(11):e51003. doi: 10.1371/journal.pone.0051003. Epub 2012 Nov 30.

15.

Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression?

Bell JL, Wächter K, Mühleck B, Pazaitis N, Köhn M, Lederer M, Hüttelmaier S.

Cell Mol Life Sci. 2013 Aug;70(15):2657-75. doi: 10.1007/s00018-012-1186-z. Epub 2012 Oct 16. Review.

16.

Regulation of IMP3 by EGFR signaling and repression by ERβ: implications for triple-negative breast cancer.

Samanta S, Sharma VM, Khan A, Mercurio AM.

Oncogene. 2012 Nov 1;31(44):4689-97. doi: 10.1038/onc.2011.620. Epub 2012 Jan 23.

17.

Insulin growth factor-2 binding protein 3 (IGF2BP3) is a glioblastoma-specific marker that activates phosphatidylinositol 3-kinase/mitogen-activated protein kinase (PI3K/MAPK) pathways by modulating IGF-2.

Suvasini R, Shruti B, Thota B, Shinde SV, Friedmann-Morvinski D, Nawaz Z, Prasanna KV, Thennarasu K, Hegde AS, Arivazhagan A, Chandramouli BA, Santosh V, Somasundaram K.

J Biol Chem. 2011 Jul 22;286(29):25882-90. doi: 10.1074/jbc.M110.178012. Epub 2011 May 25.

18.

Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival.

Schaeffer DF, Owen DR, Lim HJ, Buczkowski AK, Chung SW, Scudamore CH, Huntsman DG, Ng SS, Owen DA.

BMC Cancer. 2010 Feb 23;10:59. doi: 10.1186/1471-2407-10-59.

19.

p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis.

Tsoumpou I, Arbyn M, Kyrgiou M, Wentzensen N, Koliopoulos G, Martin-Hirsch P, Malamou-Mitsi V, Paraskevaidis E.

Cancer Treat Rev. 2009 May;35(3):210-20. doi: 10.1016/j.ctrv.2008.10.005. Epub 2009 Mar 3. Review.

20.

Frozen-section evaluation of cervical adenocarcinoma at time of radical trachelectomy: pathologic pitfalls and the application of an objective scoring system.

Park KJ, Soslow RA, Sonoda Y, Barakat RR, Abu-Rustum NR.

Gynecol Oncol. 2008 Sep;110(3):316-23. doi: 10.1016/j.ygyno.2008.05.029. Epub 2008 Jul 17.

Supplemental Content

Support Center